Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Scales Back Domestic Inspections Due To Coronavirus

Agency Will Focus On Safety Of Regulated Products

Executive Summary

After postponing foreign inspections, the US FDA has further decided to scale back domestic inspections due to the coronavirus outbreak.

You may also be interested in...



FDA Guides On COVID-19 Obstacles To ANDA Studies

Specific guidance for ANDA sponsors on bioequivalence studies during the COVID-19 pandemic has been published by the US FDA.

Jubilant Sees No Material Impact From Coronavirus-Led Plant Closure, For Now

Jubilant Life Sciences anticipates continued strong demand despite temporary logistics blips in India and expects to resume operations at its Nanjangud plant, currently shut down due to a few COVID-19 cases among employees, by mid-April. It is also evaluating the feasibility of manufacturing some of the APIs recently incentivized by the Indian government.

FDA Postpones Foreign Inspections Due To Coronavirus Outbreak

The US FDA is postponing “most foreign inspections” through April as a result of the coronavirus outbreak, because it will temporarily not be able to physically inspect foreign produced FDA-regulated products or manufacturers. However, inspections outside the US deemed as critical “will still be considered on a case-by-case basis.”

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB149739

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel